China Biologic Products
| Company type | Private (since 2021) Public (prior to 2021) |
|---|---|
| Nasdaq: CBPO | |
| Industry | Biotechnology |
| Headquarters | , |
| Website | www |
China Biologic Products, Inc., through its indirect majority-owned subsidiary Shandong Taibang, is the only blood plasma-based biopharmaceutical company approved by the government of Shandong Province.
Background[edit]
The company is engaged in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Plasma-based human albumin is used mainly to increase blood volume while Immunoglobulin is used for disease prevention and treatment.
Previously listed on the Nasdaq, in April 2021, it was taken private in a $4.6 billion deal by an investor group that included Centurium Capital, CITIC Capital and Hillhouse Capital.[1]
References[edit]
- ^ "PE investors complete $4.6b China Biologic take-private | AVCJ". AVCJ. 2021-04-22. Retrieved 2023-12-30.